Citation: Usman Mahmood, David W Johnson, Magid A Fahim. Cardiac biomarkers in dialysis[J]. AIMS Genetics, 2017, 4(1): 1-20. doi: 10.3934/genet.2017.1.1
[1] | Nalin Fonseka, Jerome Goddard Ⅱ, Alketa Henderson, Dustin Nichols, Ratnasingham Shivaji . Modeling effects of matrix heterogeneity on population persistence at the patch-level. Mathematical Biosciences and Engineering, 2022, 19(12): 13675-13709. doi: 10.3934/mbe.2022638 |
[2] | Chanakarn Kiataramkul, Graeme Wake, Alona Ben-Tal, Yongwimon Lenbury . Optimal nutritional intake for fetal growth. Mathematical Biosciences and Engineering, 2011, 8(3): 723-732. doi: 10.3934/mbe.2011.8.723 |
[3] | Chang-Yuan Cheng, Kuang-Hui Lin, Chih-Wen Shih . Coexistence and extinction for two competing species in patchy environments. Mathematical Biosciences and Engineering, 2019, 16(2): 909-946. doi: 10.3934/mbe.2019043 |
[4] | Bapi Saha . Chance of extinction of populations in food chain model under demographic stochasticity. Mathematical Biosciences and Engineering, 2019, 16(5): 3537-3560. doi: 10.3934/mbe.2019177 |
[5] | Chang-Yuan Cheng, Shyan-Shiou Chen, Xingfu Zou . On an age structured population model with density-dependent dispersals between two patches. Mathematical Biosciences and Engineering, 2019, 16(5): 4976-4998. doi: 10.3934/mbe.2019251 |
[6] | Lazarus Kalvein Beay, Agus Suryanto, Isnani Darti, Trisilowati . Hopf bifurcation and stability analysis of the Rosenzweig-MacArthur predator-prey model with stage-structure in prey. Mathematical Biosciences and Engineering, 2020, 17(4): 4080-4097. doi: 10.3934/mbe.2020226 |
[7] | Kuang-Hui Lin, Yuan Lou, Chih-Wen Shih, Tze-Hung Tsai . Global dynamics for two-species competition in patchy environment. Mathematical Biosciences and Engineering, 2014, 11(4): 947-970. doi: 10.3934/mbe.2014.11.947 |
[8] | S.A. Gourley, Yang Kuang . Two-Species Competition with High Dispersal: The Winning Strategy. Mathematical Biosciences and Engineering, 2005, 2(2): 345-362. doi: 10.3934/mbe.2005.2.345 |
[9] | Lifeng Han, Steffen Eikenberry, Changhan He, Lauren Johnson, Mark C. Preul, Eric J. Kostelich, Yang Kuang . Patient-specific parameter estimates of glioblastoma multiforme growth dynamics from a model with explicit birth and death rates. Mathematical Biosciences and Engineering, 2019, 16(5): 5307-5323. doi: 10.3934/mbe.2019265 |
[10] | Alejandro Rincón, Fredy E. Hoyos, John E. Candelo-Becerra . Comparison, validation and improvement of empirical soil moisture models for conditions in Colombia. Mathematical Biosciences and Engineering, 2023, 20(10): 17747-17782. doi: 10.3934/mbe.2023789 |
Nomenclature
A coefficient in van Deemter equation (7) (m)
B coefficient in van Deemter equation (7) (m2/s)
Bb Bed permeability (m2/s)
C coefficient in van Deemter equation (7) (s)
c protein concentration in the mobile phase (M)
dp Particle diameter (m)
Dax axial dispersion coefficient (m2/s)
Dm molecular diffusivity in mobile phase (m2/s)
De effective diffusivity (m2/s)
h reduced HETP (= H/dp)
H Height equivalent to plate number (HETP) (m)
L length of the column (m)
ΔP column pressure drop (Pa)
u0 Superficial velocity of the fluid (m/s)
Vc column volume (m3)
Greek symbols
εc column void fraction
εp Intra-particle void fraction
εt total column void fraction
η mobile phase viscosity (Pa.s)
μ1 first moment of pulse response peak (s)
μ2 second moment of pulse response peak
Dimensionless transport parameters
Pe Péclet number (= uint L/Dax)
Re Reynolds number (= ρudp/η)
Sc Schmidt number (= η/ρDm)
Ion-exchange chromatography was introduced in the mid-1940s as a separation technique based on charge properties of molecular species [1]. Within the last few decades, there has been an increasing interest in liquid chromatographic processes because of the developing biotechnology scope and demands from the pharmaceutical and chemical industries for extremely particular and productive separation methods. Today, IEC is being employed for purification of proteins, peptides, nucleic acids and other charged biomolecules. IEC technique is well-suited for capture, intermediate purification or polishing steps in a purification protocol. IEC columns are commercially available from several suppliers, ranging from microscale purification and analysis through to purification of kilograms of product.
With increased commercial usage, in-depth understanding of different mechanisms within chromatography columns is desirable in order to achieve optimum performance. Regardless of intended application, operators seek a common set of performance characteristics such as high capacity and recovery, reproducibility, purification factor and a high degree of process control. Development of methods for protein purification processes is preferably done at small scale typically to obtain a robust, scalable process with the highest possible performance at the minimal cost without compromising with the product quality. This has stimulated much research to study the principles of preparative chromatography and the important subject of scale-up.
The performance of a chromatography column rests on elements of design and operational factors. Several studies have been focused on the determination of the experimental settings and column design parameters of separations in preparative chromatography. Atamna et al. [2] studied the effect of column diameter on resolution and efficiency with four different diameters using constant length columns. Gritti and Guichon [3] explained the theoretical and experimental investigations of the impact of the column diameter to the average particle size on the column performance that manufacturers of narrow-bore and/or capillary columns with small bed aspect ratio are facing.
Rathore and Velayudhan [4,5] presented an overview of the fundamentals and practices of scale-up in preparative chromatography. Modes of interaction and modes of operation are defined to clarify the choices available in the course of scale-up. The scaling-up of ion-exchange processes for protein separation has been reported in several studies. For example, Levison et al. [6] investigated an ovalbumin separation from hen egg-white on the anion exchange with a 1000-fold scale-up. Fibrous cellulose-based ion-exchangers were operated at high flow rates in a process-scale system demonstrating no loss of capacity or binding efficiency for the target proteins. Gerberding and
Byers [7] described a preparative anion exchange processing of proteins from dairy whey scaling from 5 cm to 140 cm column diameter to an economically optimized production level operation. According to the theory, an effective scale-up can be achieved by holding the retention factor of the components inside the column constant [8,9,10]. This means that the flow rate, loading and gradient length are scaled to the column volume. Thus, one must decide on column dimension. The key point in scale-up is the concept of time scales. The time scales involved are the time scales for flow, mass transfer, and dispersion. When scaling up or scaling down, processes of similarity will be processes, which have identical time scales [11].
It should be emphasized that many of the comparative issues and scale-up challenges are associated with momentum and mass-transfer problems in a large-scale production process. The combined effects of convection, axial dispersion, mass transfer within the particle pores, and sorption rate limitations reduce the performance [12,13,14,15]. Column performance can also be affected by other factors such as protein denaturation [16] and extra-column effects [17]. Depending on specific conditions, one or more of these mechanisms may dominate contributions to band broadening and peak asymmetry (fronting and tailing) or distortions [12,18], which can considerably affect separation effectiveness[19]. Some process procedures can be difficult to control, may suffer from a lack of reproducibility and involve significant losses of product. The feasibility and successful application of ion-exchange chromatography in the purification of proteins at pilot and process scale remains to be demonstrated.
A preparative chromatography study was conducted to investigate the effect of operation conditions on the dynamic adsorptive behavior of proteins in a commercialized strong cation ion-exchange SP Sepharose Fast Flow (SP FF). As separation efficiency relies on the flow properties of the column, the flow distribution was first observed under a non-binding condition loading an acetone solution. Prior to carry out the scale-up calculations, it is essentially necessary to figure out which mass transfer mechanism is controlling the ion-exchange process. The diffusion mechanism is often dominated mass transfer resistance for protein chromatography. To check if this hypothesis was the case for minor whey proteins and in particular lactoperoxidase, the height equivalent to plate number (HETP) and breakthrough profiles were determined for two columns with different diameters. The bed height was kept the same to maintain kinetic and dynamic equivalence. We investigated HETP as a function of velocity for LP and LF under non-binding conditions. LP breakthrough curves were then obtained at different flow rates and LP loading concentrations. The dynamic binding capacity at 10% breakthrough was calculated and compared for the both columns. Finally, the column efficiency in terms of HETP as well as dynamic binding capacity of the column performance for two different scales was evaluated.
Lactoperoxidase and lactoferrin from bovine milk both ≥ 90% purity were used. For elution under non-retained conditions, the elution buffer was prepared from 20 mM solution of Na2HPO4 and NaH2PO4, by adding 1 M NaCl adjusted to pH 6.7. For breakthrough studies under retained conditions, the running buffer was phosphate buffer saline (PBS), adjusted to pH 6.7. All chemical reagents used in the present work were purchased from Sigma-Aldrich (Oakville, Canada), except acetone and HCl from Caledon. Ultra-pure water was obtained using a Milli-Q system (Barnstead easy-pure RODI equipped with 0.2 μm filter, Fisher Scientific). Prior to use, all buffer solutions were filtered through a hydrophilic polypropylene membrane filter with a 0.2 μm pore size (PALL life Sciences, Canada) and de-gassed.
The 90μm SP Sepharose prepacked HiScreenTM and HiPrepTM columns (7.7 mm × 100 mm and 16 mm × 100 mm) were used from GE Healthcare (Mississauga, Canada). The experiments were carried out on the ÄKTA purifier 100 system (GE Healthcare Life Sciences, Canada), which includes two system pumps, a fraction collector and monitors for multi-wavelength UV absorption, pH, and conductivity. UNICORNTM 5.31 software was used for data acquisition and system control. The flow rate accuracy was checked by directly collecting the mobile phase in the absence of column at room temperature and displayed the long-term accuracy. The dead volume of the experimental device and void volumes of two columns were estimated from the elution volumes of acetone and dextran respectively corrected for the extra-column contribution.
Parameter | HiScreenTM SP FF | HiPrepTM SP FF |
Column length (mm) | 100 | 100 |
Column i.d. (mm) | 7.7 | 16 |
Median particle size (μm) | 90 | 90 |
Column voidage | 0.296 | 0.273 |
Particle voidage | 0.893 | 0.856 |
Total voidage | 0.917 | 0.895 |
The system dispersion curve was measured using a phosphate buffer containing 3% (v/v) acetone. The non-binding breakthrough data were fitted to Eq. 1 to determine the Péclet number (Pe) using least squares regression [20]. For mass transfer, the dimensionless Pe number describes the relative rate of convection and diffusion. In Eq. (1), c is the outlet effluent concentration, c0 is the solute loading concentration, Vloading is the volume of acetone solution loaded, and V50 is the loaded volume when c/c0 = 0.50.
cc0=12{1+erf(Pe1/2(Vloading−V50)2(VloadingV50)1/2)} | (1) |
A concentration of 0.2 mg/mL for each protein was used. The experimental protocol is as follows: 1% CV of each protein solution is injected into the column through in which the buffer solution is flowing through. Similar to non-binding breakthrough, the binding experiments were monitored by recording the UV absorbance of protein at 280 nm at the column exit. Each experiment was conducted at different flow rates between 0.8-3.5 mL/min and 1.68-5.8 mL/min corresponding to linear velocities of 1.74-7.52 cm/min for HiScreenTM and 1.74-2.90 cm/min HiPrepTM columns respectively. All experiments were carried out at room temperature. Table 2 summarizes the experimental conditions used. It should be noted that volumes of 47 μL and 200 μL of protein samples (equivalent to 1% CV) were injected into the 7.7 mm × 100 mm and the 16 mm × 100 mm column in order to maintain constant sample loading per unit of column cross-section area.
Protein | LP and LF |
Concentration (mg/mL) | 0.2 |
Injection volume (μL) | 47*, 200** |
Flow velocity (cm/min) | 1.74, 2.50, 3.33, 4.50, 5.82, 6.67, 7.52*, 0.84, 1.00, 1.74, 2.00, 2.50, 2.88** |
Buffer | 20 mM NaH2SO4+ Na2HPO4, 1 M NaCl pH 6.7 |
Temperature (℃) | 22-22.5 |
*HiScreenTM column, **HiPrepTM column |
Only lactoperoxidase (LP) was used for these studies. The breakthrough curves were measured at different LP concentrations (0.02, 0.06, 0.1, 0.5 and 1 mg/mL) and flow velocities (1.74, 2.00, 2.50, 2.90 cm/min). The loading step with the protein solution was stopped after the outlet concentration of the column reached to the feed solution absorbance, afterwards the column was washed using 20 mM sodium phosphate + 1 M NaCl solution for 5 CV, followed by phosphate buffers for 5 CV of each. To compare the adsorption performance on two columns, the dynamic binding capacity at 10% breakthrough (DBC10%) was calculated using Eq. (2), where c is the LP outlet concentration, c0 is the LP loading concentration, V10%is the loading volume of LP solution when c/c0 = 0.10 and Vc is the volume of the column.
DBC10%=c0V10%∫0(1−cc0)dVloadingVc | (2) |
All experiments were carried out at room temperature, operating conditions of which are reported in Table 3.
Protein | LP |
Concentration (mg/mL) | 0.02, 0.03, 0.06, 0.1, 0.5, 1 |
Flow velocity (cm/min) | 1.74, 2, 2.50, 2.80 |
Buffer | 20 mM NaH2SO4+ Na2HPO4, pH 6.7 |
Temperature (℃) | 22-22.5 |
Physical insights on the flow distribution are particularly important for understanding and predicting the transport of molecules through the column particularly due to low Reynolds
number (Re) which is typical in protein chromatography. For each column, the acetone breakthrough curve was measured under non-binding conditions. As can be seen in Figure 1, the typical breakthrough curves obtained for both columns are identical. All following breakthrough profiles for HiPrepTM SP FF takes place later due to its larger void volume. The Pe number values were estimated from Eq. (1) and summarized in Table 4. The Pe values are comparatively identical for each column; the higher Pe numbers are preferred as they correspond to a uniform distribution of flow to the inlet surface of the column as well as uniform distribution of the binding site properties. At higher Pe values, the breakthrough curve tends to approach ideality and breakthrough corresponds to the capacity of the media. Indeed, higher efficiency due to less back mixing and shorter required time for diffusion can be achieved with higher flow rates.
Chromatography column | HiScreenTM SP FF | HiPrepTM SP FF | ||||||
Velocity (cm/min) | 3.333 | 4.946 | 5.828 | 7.527 | 0.836 | 2.488 | 2.985 | 3.333 |
Pe (-) | 35.01 ± 0.87 | 38.59 ± 0.91 | 37.49 ± 0.9 | 38.14 ± 0.97 | 190.3 ± 5.2 | 204.9 ± 4.6 | 196.7 ± 4.7 | 189 ± 5.4 |
In laminar flow, the pressure drop ΔP across a bed of length L packed with particles of diameter dp is given by Darcy's law:
ΔP=ηu0L/Bb | (3) |
where η is the dynamic viscosity and Bb=ε3cd2p/150(1−εc)2 is the bed permeability, which depends on bed structure properties. This parameter is closely associated to resistance to mass transfer. For the HiScreenTM, bed permeability is calculated to be Bb=2.83×10−8 and for HiPrepTM Bb=3.01×10−8cm2/s.Using these permeability values, the pressure drop ΔP can be estimated as a function of linear velocity u0 (Figure 2). The large SP FF media pore size around 45-145 μm is a possible cause of this low backpressure which is an advantage for the operation. Both geometries show similar pressure values specifically at lower velocities due to their identical column height (10 cm). However, as can be seen in Figure 2, the pressure was slightly higher with HiScreenTM column for the reason that it has smaller cross-section area. It should be noted that the instrumentation employed in this study was not equipped with a pressure detector. Thus, the column pressure drop was only estimated and compared for the two columns.
The peak responses were recorded at a wavelength of 280 nm for both LP and LF. For each of these flow rates and for each sample, the extra column contributions to the retention volume and to the band broadening of probes were measured by replacing the chromatographic column with a ZDV union connector. The experimental HETP data measured for the columns were corrected for the contribution of the ÄKTA FPLC system. The extra-column and the total band variances were measured according the numerical integration method. In this method, the data points (ti, ci) were considered and the true first and second central moments were calculated as follows:
μ1=∫t0c(t)tdt∫t0c(t)dt | (4) |
μ2=∫t0c(t)(t−μ1)2dtt∫0c(t)dt | (5) |
The moments were calculated based on the decomposition of the peak area into a series of elementary trapezes. The corrected reduced HETP, h=HETP/dp, was given by:
h=Ldpμ2−μ2,ex(μ1−μ1,ex)2 | (6) |
where μ1, ex and μ2, exare the first and second central moments of the extra column band profiles.
Chromatographic peaks for the two proteins (LP and LF) obtained at various flow rates on SP FF medium are shown respectively in Figure 3.
A useful approach for the empirical characterization of column efficiency is based on van Deemter plot [21], which is used to assess the relative importance of dispersive and mass transfer kinetics. The experimental peaks for each protein in elution chromatography (Figure 3) were used to calculate HETP at various flow rates according to the numerical integration method described in previous section. The modified van Deemter equation adapted from [22] describes the effects of perfusion in a packed column:
H=A+Bu0+Cf(λ)u0 | (7) |
In practical HPLC applications, A=2dp and B=2Dm; since the order of molecular diffusivity (Dm) is of 10−7cm2/s for proteins, the second term in Eq. (7) becomes negligibly small. The contribution of intra-particle convection becomes one at low flow rates. Thus, the slope of HETP vs. u0 is simply and in terms of reduced HETP, i.e. h=H/dp, can be written as:
dhdu0=C=130ν(1+ν)2εpεcdpDe | (8) |
where εc external porosity, εp internal porosity and ν is ((1−εc)/εc)εp.
After initial rapid increase in HETP, the plot tends to a plateau at higher velocities expressed by Eq. (9). As u0 increases, the slope of HETP plot changes and mass transport becomes dominated by intra-particle convection [23].
hplateau=A+35ν(1+ν)2εpεcBbBp | (9) |
Figure 4 illustrates the reduced HETP as a function of the superficial velocity that increases linearly with velocity for both proteins. The shape of HETP indicates the association with pore diffusion as the controlling mechanism of mass transport. It is essentially true as protein transport is restricted by diffusional hindrance due to large molecular configuration. This effect is even more remarkable for the two proteins of interest in this study. Indeed, as in our previous study, lactoperoxidase showed a high shielding factor indicating its hindrance impact on mass transport mechanism.
To check reproducibility, two separate columns for each diameter were used and evaluated. For analysis, a single modified van Deemter plot is fitted to the two separate column data sets for each I.D. The data points collected for two columns at each column diameter were virtually superimposable. Rather than averaging the end results of two separate columns, the data from each column was combined for a single modified van Deemter fit. The fitted parameters of A and C were calculated by using SigmaPlot from Systat Software Inc. The values for reduced A term were found to be 0.016 and 0.023 for the studied columns. These values are in a good agreement with the estimation of A which equals 0.018 for SP FF. The reduced plate height for the test columns slightly increased with the slope (C term) of 6.02 and 6.90 for 7.7 and 16 mm I.D. column, respectively. A similar trend was observed by Patel et al. [24]. They reported that the van Deemter A term and C term coefficient exhibited an increase with increasing column diameter. The results clearly show that both columns offer a similar chromatographic performance for studied proteins.
For our experiments, the maximum linear velocity never exceeded 8 cm/min primarily due to pressure limitation of the columns. Thus, for the applied range of study no plateau was observed.
Chromatography columns are often characterized by the shape of their breakthrough curves. The breakthrough curve shape is governed by transport processes, heat effects, and adsorption kinetics within the functionalized adsorbent and by fluid hydrodynamics in the hold-up volumes of the columns. Commercial chromatography columns are optimized such as to obtain breakthrough curves that are as sharp as possible, in order to minimize buffer consumption and to maximize the utilized adsorbent capacity.
As the operating conditions having major influence on the performance of the adsorbent are the flow rate of the mobile phase and the protein loading concentration in the feed, the effect of these two operating conditions is experimentally studied. The obtained breakthrough curves for LP exhibited sharp breakthrough curves in most cases with both columns. The shape of the LP breakthrough curves was not rectangular, as seen for an ideal adsorbent [25]; yet symmetric in terms of the stoichiometric breakthrough time. One explanation for such a behavior could be the contribution of non-ideal effects such as dispersion effects due to pore size and length distribution. Another explanation could be the protein adsorption kinetic on the sulphopropyl (SP) strong cation exchange groups on the adsorbent surface. At high protein loadings, accessibility to the binding sites are further reduced and therefore diffusive transport limitations will be increased.
To study the impact of flow rate on the adsorption of LP on SP FF columns with two different diameters, dynamic adsorption experiments were carried out at flow rate between 1.74 cm/min and 2.80 cm/min. The flow rate was adjusted in order to obtain about the same linear velocity. The LP loading concentration was held constant at 0.03 mg/mL. The experimental breakthrough curves were plotted against the corrected LP loading volume (Vloading-V0) divided by CV (Figure 5). For both geometries, the breakthrough curves were unchanged at the operating range of flow rate. This confirms that it is likely to maintain the quality of the separation and to avoid any product stability issues at small scale and directly apply to the larger column with no flow rate effect. The obtained residence time of the loading acetone solution as a non-interacting tracer in the void volume was similar for both columns, i.e. at the flow velocity of 4.9 cm/min was equal to 1.88 and 1.80 min for HiScreenTM and HiPrepTM columns respectively. This generally indicates that the mass transfer mechanism is limited to diffusive transport.
The influence of feed loading concentration on breakthrough behaviour of LP was investigated at 0.02, 0.06, 0.1, 0.5 and 1 mg/mL LP for a flow velocity of 2.5 cm/min. The breakthrough curves were compared by plotting c/c0 as a function of the corrected loading volume of LP solution multiplied by the inlet concentration (c0) and divided by CV. Figure 6 illustrates the LP breakthrough curves at different LP loading concentrations for HiScreenTM and HiPrepTM columns respectively. For both columns, the profile of the breakthrough curves was uninfluenced by the feed concentration. However, the breakthrough occurs unexpectedly earlier at lower loading concentrations. This non-traditional behavior may be due to high amount of phosphate buffer (200 mM) present; the SP functional group of cation exchange has a great preference for sodium ions. With increasing LP concentration, the preference for LP over sodium ions takes turn resulting in a later breakthrough and higher dynamic capacity. van Beijeren et al. [25] also reported an increasing in binding capacity with increasing protein loading concentration for cation exchange membrane chromatography.
Dynamic binding capacity (DBC) clarifies the impact of mass transfer limitations that may occur as flow rate is increased; it is much more useful in predicting real process performance. DBC is measured under operating conditions to obtain information on what the maximum load of the target protein to the column should be in order to prevent additional loss. For each column, the dynamic binding capacities at 10% breakthrough (DBC10%) were determined from the breakthrough curves attained at different flow rates. DBC10%was plotted as a function of superficial velocity in Figure 7. A negligible decrease with increased feed flow velocity can be observed, i.e. the dynamic binding capacity at 2.5 cm/min feed flow velocity being only 1.5% lower than that at 1.74 cm/min. In fact, less dependency of DBC on velocity is in agreement with results of HETP implying that protein uptake is controlled by pore diffusion. A decrease in dynamic binding capacity at increased flowrate for the adsorption of proteins on cation exchange was also observed for LF by Billakanti et al. [27], who found 15% decrease in DBC upon an increase of flow rate by a factor of five.
In this study, the highest DBC10%was obtained for the column with the larger column. For the 20 mL column, the LP binding capacity per unit of adsorbent volume was found around 20% higher than the one obtained with the 4.7 mL column. It is likely due to better flow distribution leading to deeper penetration of protein into the particles throughout the HiPrepTM column, which ultimately results in increasing binding capacity.
The dynamic binding capacity was also determined as a function of LP loading concentration. Figure 8 shows the concentration effect for both columns. Each column shows comparable results in the DBC10%with increasing the LP loading concentration. The DBC10%at 0.02 mg/mL was 1.96 and 2.40 mg/mL for HiScreenTM and HiPrepTM columns, respectively. As the inlet concentration increased to 1 mg/mL, these values increased to 5.04 and 6.12 mg/mL, corresponding to 1.57 and 1.55 fold increase in binding capacity. As previously described, this phenomenon might be due to the charge repulsion between proteins in the mobile phase and proteins adsorbed on the adsorbent and/or higher LP concentration. In addition, the obtained breakthrough curve beforehand at a concentration of 0.03 mg/mL and 2.5 cm/min is consistent with the result observed at the loading concentration range between 0.02 and 1 mg/mL. At these various loading concentrations, the binding capacities were lower with the HiScreenTM column, due to its smaller column diameter.
In this study, the influence of operating conditions on the adsorption of LP and LF on cation exchange adsorbent was experimentally investigated. In theory, the profiles should be similar due to the fact that the bed height, i.e. the flow path length through the column was kept equal. It was observed that under the same bed height at both scales comparable results of back pressure and breakthrough profiles can be obtained. The process efficiency in terms of the height equivalent to a theoretical plate (HETP) as well as the dynamic binding capacity was evaluated. Trends of HETP as a function of reduced velocity were consistent with two columns representing almost a constant efficiency for the increased column dimension. This indicates that efficiency could be expected to remain unchanged in scale-up step. The LP breakthrough curves were measured at various flow rates and loading concentrations. It was observed that the LP dynamic binding capacity at 10% breakthrough capacity was independent of the applied flow rate for two geometries. This proves the advantage of column chromatography, for which high flow rates can be used without decreasing the dynamic binding capacity in larger scales. Moreover, the dynamic binding capacity decreased at higher LP concentrations, which may be as a result of competitive adsorption between sodium ions and protein. A profound understanding of the impact of non-ideal effects particularly at high protein loadings on the rate of mass transport and adsorption is required for further optimization of ion-exchange adsorbent materials.
Overall, according to reproducibility and comparable results at larger scale in this study, scale-up of minor whey proteins separation can be accomplished by increasing column diameter while maintaining a constant column bed length and linear velocity. Although it leads to lower flow velocities, this approach has the advantage of reduced non-ideal flow distribution compared to small scale.
All authors declare no conflicts of interest in this paper.
[1] |
Cheung AK, Sarnak MJ, Yan G, et al. (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65: 2380-2389. doi: 10.1111/j.1523-1755.2004.00657.x
![]() |
[2] |
Foley RN, Parfrey PS, Harnett JD, et al. (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192. doi: 10.1038/ki.1995.22
![]() |
[3] | ANZDATA Registry. 38th Report, Chapter 3: Mortality in End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2016. |
[4] |
Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-119. doi: 10.1053/ajkd.1998.v32.pm9820470
![]() |
[5] |
Longenecker JC, Coresh J, Powe NR, et al. (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13: 1918-1927. doi: 10.1097/01.ASN.0000019641.41496.1E
![]() |
[6] |
Ruilope LM, van Veldhuisen DJ, Ritz E, et al. (2001) Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787. doi: 10.1016/S0735-1097(01)01627-8
![]() |
[7] |
Agarwal R (2005) Hypertension in chronic kidney disease and dialysis: pathophysiology and management. Cardiol Clin 23: 237-248. doi: 10.1016/j.ccl.2005.03.003
![]() |
[8] |
Neumann J, Ligtenberg G, Klein II, et al. (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65: 1568-1576. doi: 10.1111/j.1523-1755.2004.00552.x
![]() |
[9] |
Covic A, Kothawala P, Bernal M, et al. (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24: 1506-1523. doi: 10.1093/ndt/gfn613
![]() |
[10] |
Kaysen GA, Eiserich JP (2004) The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15: 538-548. doi: 10.1097/01.ASN.0000111744.00916.E6
![]() |
[11] |
Wang AY, Lam CW, Chan IH, et al. (2010) Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 56: 210-216. doi: 10.1161/HYPERTENSIONAHA.110.151167
![]() |
[12] | Martinez-Rumayor A, Richards AM, Burnett JC, et al. (2008) Biology of the natriuretic peptides. Am J Cardiol 101: 3-8. |
[13] | Mukoyama M, Nakao K, Hosoda K, et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412. |
[14] |
Yasue H, Yoshimura M, Sumida H, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203. doi: 10.1161/01.CIR.90.1.195
![]() |
[15] | Gerbes AL, Dagnino L, Nguyen T, et al. (1994) Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 78: 1307-1311. |
[16] | Kinnunen P, Vuolteenaho O, Ruskoaho H (1993) Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132: 1961-1970. |
[17] | Bruneau BG, Piazza LA, de Bold AJ (1997) BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273: H2678-2686. |
[18] |
Liang F, Gardner DG (1999) Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 104: 1603-1612. doi: 10.1172/JCI7362
![]() |
[19] |
Bibbins-Domingo K, Ansari M, Schiller NB, et al. (2003) B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108: 2987-2992. doi: 10.1161/01.CIR.0000103681.04726.9C
![]() |
[20] |
de Bold AJ (2009) Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 57: 29-32. doi: 10.2310/JIM.0b013e3181948b37
![]() |
[21] | Bruneau BG, Piazza LA, de Bold AJ (1996) Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Endocrinology 137: 137-143. |
[22] |
Wiese S, Breyer T, Dragu A, et al. (2000) Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102: 3074-3079. doi: 10.1161/01.CIR.102.25.3074
![]() |
[23] |
Maisel AS, Krishnaswamy P, Nowak RM, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167. doi: 10.1056/NEJMoa020233
![]() |
[24] |
McCullough PA, Nowak RM, McCord J, et al. (2002) B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416-422. doi: 10.1161/01.CIR.0000025242.79963.4C
![]() |
[25] |
Doust JA, Pietrzak E, Dobson A, et al. (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Bmj 330: 625. doi: 10.1136/bmj.330.7492.625
![]() |
[26] |
Troughton RW, Frampton CM, Yandle TG, et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355: 1126-1130. doi: 10.1016/S0140-6736(00)02060-2
![]() |
[27] |
Pfisterer M, Buser P, Rickli H, et al. (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Jama 301: 383-392. doi: 10.1001/jama.2009.2
![]() |
[28] |
Berger R, Moertl D, Peter S, et al. (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55: 645-653. doi: 10.1016/j.jacc.2009.08.078
![]() |
[29] |
Eurlings LW, van Pol PE, Kok WE, et al. (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 56: 2090-2100. doi: 10.1016/j.jacc.2010.07.030
![]() |
[30] |
Persson H, Erntell H, Eriksson B, et al. (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study—Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 12: 1300-1308. doi: 10.1093/eurjhf/hfq169
![]() |
[31] |
Lainchbury JG, Troughton RW, Strangman KM, et al. (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55: 53-60. doi: 10.1016/j.jacc.2009.02.095
![]() |
[32] |
Shah MR, Califf RM, Nohria A, et al. (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17: 613-621. doi: 10.1016/j.cardfail.2011.04.012
![]() |
[33] |
Karlstrom P, Alehagen U, Boman K, et al. (2011) Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 13: 1096-1103. doi: 10.1093/eurjhf/hfr078
![]() |
[34] |
Januzzi JL, Jr., Rehman SU, Mohammed AA, et al. (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58: 1881-1889. doi: 10.1016/j.jacc.2011.03.072
![]() |
[35] |
Jourdain P, Jondeau G, Funck F, et al. (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49: 1733-1739. doi: 10.1016/j.jacc.2006.10.081
![]() |
[36] |
Anguita M, Esteban F, Castillo JC, et al. (2010) [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure]. Med Clin (Barc) 135: 435-440. doi: 10.1016/j.medcli.2009.11.048
![]() |
[37] |
Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. (2014) Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 35: 1559-1567. doi: 10.1093/eurheartj/ehu090
![]() |
[38] |
Mant J, Al-Mohammad A, Swain S, et al. (2011) Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 155: 252-259. doi: 10.7326/0003-4819-155-4-201108160-00009
![]() |
[39] |
van Kimmenade RR, Januzzi JL, Jr., Bakker JA, et al. (2009) Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53: 884-890. doi: 10.1016/j.jacc.2008.11.032
![]() |
[40] |
Tsai SH, Lin YY, Chu SJ, et al. (2010) Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 51: 151-163. doi: 10.3349/ymj.2010.51.2.151
![]() |
[41] | Januzzi JL, van Kimmenade R, Lainchbury J, et al. (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27: 330-337. |
[42] |
Gutierrez OM, Tamez H, Bhan I, et al. (2008) N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 54: 1339-1348. doi: 10.1373/clinchem.2007.101691
![]() |
[43] |
Wang AY, Lam CW, Yu CM, et al. (2007) N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 18: 321-330. doi: 10.1681/ASN.2005121299
![]() |
[44] |
Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50: 1009-1019. doi: 10.1053/j.ajkd.2007.08.017
![]() |
[45] |
Paniagua R, Amato D, Mujais S, et al. (2008) Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 3: 407-415. doi: 10.2215/CJN.03820907
![]() |
[46] | David S, Kumpers P, Seidler V, et al. (2008) Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 23: 1370-1377. |
[47] | Parfrey PS (2000) Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 15 Suppl 5: 58-68. |
[48] |
Fahim MA, Hayen A, Horvath AR, et al. (2015) N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol 10: 620-629. doi: 10.2215/CJN.09060914
![]() |
[49] | Lippi G, Tessitore N, Luca Salvagno G, et al. (2007) Influence of haemodialysis on the NT-proBNP plasma concentration. Clin Chem Lab Med 45: 1414-1415. |
[50] |
Wahl HG, Graf S, Renz H, et al. (2004) Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 50: 1071-1074. doi: 10.1373/clinchem.2003.030692
![]() |
[51] |
Clerico A, Caprioli R, Del Ry S, et al. (2001) Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 24: 24-30. doi: 10.1007/BF03343804
![]() |
[52] |
Racek J, Kralova H, Trefil L, et al. (2006) Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 103: c162-172. doi: 10.1159/000092914
![]() |
[53] |
Dautin G, Boudjeltia S, Soltani Z, et al. (2007) The changes in NT-proBNP plasma concentrations during dialysis are highly dependent of the dialysis membrane ultrafiltration coefficient. Clin Chim Acta 376: 237-239. doi: 10.1016/j.cca.2006.08.004
![]() |
[54] | Bargnoux AS, Klouche K, Fareh J, et al. (2008) Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration. Clin Chem Lab Med 46: 1019-1024. |
[55] | Sheen V, Bhalla V, Tulua-Tata A, et al. (2007) The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 153: 244.e241-245. |
[56] |
Flemmer M, Rajab H, Mathena T, et al. (2008) Blood B-type natriuretic peptide and dialysis: present assessment and future analyses. South Med J 101: 1094-1100. doi: 10.1097/SMJ.0b013e318189aa56
![]() |
[57] | Chiarelli G, Beaulieu M, Taylor P, et al. (2011) Elimination of BNP by peritoneal dialysis: investigation of analytical issues. Perit Dial Int 31: 199-202. |
[58] |
Obineche EN, Pathan JY, Fisher S, et al. (2006) Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int 69: 152-156. doi: 10.1038/sj.ki.5000009
![]() |
[59] | Granja CA, Tailor PT, Gorban-Brennan N, et al. (2007) Brain natriuretic peptide and impedance cardiography to assess volume status in peritoneal dialysis patients. Adv Perit Dial 23: 155-160. |
[60] | Lee JA, Kim DH, Yoo SJ, et al. (2006) Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 26: 360-365. |
[61] |
Booth J, Pinney J, Davenport A (2010) N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin J Am Soc Nephrol 5: 1036-1040. doi: 10.2215/CJN.09001209
![]() |
[62] | Gangji AS, Helal BA, Churchill DN, et al. (2008) Association between N-terminal propeptide B-type natriuretic peptide and markers of hypervolemia. Perit Dial Int 28: 308-311. |
[63] |
Jacobs LH, van de Kerkhof JJ, Mingels AM, et al. (2010) Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant 25: 243-248. doi: 10.1093/ndt/gfp417
![]() |
[64] |
Lee SW, Song JH, Kim GA, et al. (2003) Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 41: 1257-1266. doi: 10.1016/S0272-6386(03)00358-5
![]() |
[65] | Fagugli RM, Palumbo B, Ricciardi D, et al. (2003) Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 95: c60-66. |
[66] |
Sommerer C, Beimler J, Schwenger V, et al. (2007) Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 37: 350-356. doi: 10.1111/j.1365-2362.2007.01785.x
![]() |
[67] | Bavbek N, Akay H, Altay M, et al. (2007) Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int 27: 663-668. |
[68] | Zoccali C, Mallamaci F, Benedetto FA, et al. (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12: 1508-1515. |
[69] |
Foley RN, Curtis BM, Randell EW, et al. (2010) Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5: 805-813. doi: 10.2215/CJN.07761109
![]() |
[70] |
Mallamaci F, Zoccali C, Tripepi G, et al. (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59: 1559-1566. doi: 10.1046/j.1523-1755.2001.0590041559.x
![]() |
[71] |
Choi SY, Lee JE, Jang EH, et al. (2008) Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. Nephron Clin Pract 110: c93-100. doi: 10.1159/000157622
![]() |
[72] |
Takase H, Dohi Y, Toriyama T, et al. (2011) B-type natriuretic peptide levels and cardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis: cross-sectional and observational studies. Nephrol Dial Transplant 26: 683-690. doi: 10.1093/ndt/gfq408
![]() |
[73] |
Goto T, Takase H, Toriyama T, et al. (2002) Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 92: 610-615. doi: 10.1159/000064100
![]() |
[74] |
Tripepi G, Mattace-Raso F, Mallamaci F, et al. (2009) Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension 54: 818-824. doi: 10.1161/HYPERTENSIONAHA.109.136804
![]() |
[75] |
Wang AY, Wang M, Lam CW, et al. (2011) Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clin J Am Soc Nephrol 6: 805-812. doi: 10.2215/CJN.07130810
![]() |
[76] |
Winkler K, Wanner C, Drechsler C, et al. (2008) Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 29: 2092-2099. doi: 10.1093/eurheartj/ehn278
![]() |
[77] |
Breidthardt T, Kalbermatter S, Socrates T, et al. (2011) Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. Eur J Heart Fail 13: 860-867. doi: 10.1093/eurjhf/hfr057
![]() |
[78] | Doust J (2010) Qualification versus validation of biomarkers. Scand J Clin Lab Invest Suppl 242: 40-43. |
[79] |
Katus HA, Remppis A, Scheffold T, et al. (1991) Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 67: 1360-1367. doi: 10.1016/0002-9149(91)90466-X
![]() |
[80] |
Turer AT, Addo TA, Martin JL, et al. (2011) Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol 57: 2398-2405. doi: 10.1016/j.jacc.2010.11.066
![]() |
[81] |
Hessel MH, Atsma DE, van der Valk EJ, et al. (2008) Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch 455: 979-986. doi: 10.1007/s00424-007-0354-8
![]() |
[82] |
Thygesen K, Alpert JS, Jaffe AS, et al. (2012) Third universal definition of myocardial infarction. Circulation 126: 2020-2035. doi: 10.1161/CIR.0b013e31826e1058
![]() |
[83] |
Keddis MT, El-Zoghby ZM, El Ters M, et al. (2013) Cardiac troponin T before and after kidney transplantation: determinants and implications for posttransplant survival. Am J Transplant 13: 406-414. doi: 10.1111/j.1600-6143.2012.04317.x
![]() |
[84] | Wu AH, Feng YJ, Roper L, et al. (1997) Cardiac troponins T and I before and after renal transplantation. Clin Chem 43: 411-412. |
[85] |
Fredericks S, Chang R, Gregson H, et al. (2001) Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta 310: 199-203. doi: 10.1016/S0009-8981(01)00547-2
![]() |
[86] |
Bozbas H, Korkmaz ME, Atar I, et al. (2004) Serum levels of cardiac enzymes before and after renal transplantation. Clin Cardiol 27: 559-562. doi: 10.1002/clc.4960271007
![]() |
[87] |
Ellis K, Dreisbach AW, Lertora JL (2001) Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 94: 993-996. doi: 10.1097/00007611-200194100-00011
![]() |
[88] |
Fahie-Wilson MN, Carmichael DJ, Delaney MP, et al. (2006) Cardiac troponin T circulates in the free, intact form in patients with kidney failure. Clin Chem 52: 414-420. doi: 10.1373/clinchem.2005.062307
![]() |
[89] |
Jacobs LH, van de Kerkhof J, Mingels AM, et al. (2009) Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 46: 283-290. doi: 10.1258/acb.2009.008197
![]() |
[90] |
Kumar N, Michelis MF, DeVita MV, et al. (2011) Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay. Nephrol Dial Transplant 26: 665-670. doi: 10.1093/ndt/gfq442
![]() |
[91] |
Wolley M, Stewart R, Curry E, et al. (2013) Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. Clin Kidney J 6: 402-409. doi: 10.1093/ckj/sfs122
![]() |
[92] |
Hill SA, Cleve R, Carlisle E, et al. (2009) Intra-individual variability in troponin T concentration in dialysis patients. Clin Biochem 42: 991-995. doi: 10.1016/j.clinbiochem.2009.03.027
![]() |
[93] |
Pianta TJ, Horvath AR, Ellis VM, et al. (2012) Cardiac high-sensitivity troponin T measurement: a layer of complexity in managing haemodialysis patients. Nephrology (Carlton) 17: 636-641. doi: 10.1111/j.1440-1797.2012.01625.x
![]() |
[94] | Katus HA, Haller C, Muller-Bardorff M, et al. (1995) Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis. Clin Chem 41: 1201-1203. |
[95] | Collinson PO, Stubbs PJ, Rosalki SB (1995) Cardiac troponin T in renal disease. Clin Chem 41: 1671-1673. |
[96] | Li D, Jialal I, Keffer J (1996) Greater frequency of increased cardiac troponin T than increased cardiac troponin I in patients with chronic renal failure. Clin Chem 42: 114-115. |
[97] |
Hickman PE, McGill D, Potter JM, et al. (2015) Multiple biomarkers including cardiac troponins T and I measured by high-sensitivity assays, as predictors of long-term mortality in patients with chronic renal failure who underwent dialysis. Am J Cardiol 115: 1601-1606. doi: 10.1016/j.amjcard.2015.02.066
![]() |
[98] | Lippi G, Tessitore N, Montagnana M, et al. (2008) Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med 132: 72-76. |
[99] |
Gaze DC, Collinson PO (2014) Cardiac troponin I but not cardiac troponin T adheres to polysulfone dialyser membranes in an in vitro haemodialysis model: explanation for lower serum cTnI concentrations following dialysis. Open Heart 1: e000108. doi: 10.1136/openhrt-2014-000108
![]() |
[100] | Nunes JP, Sampaio S, Cerqueira A, et al. (2015) Anti-troponin I antibodies in renal transplant patients. Rev Port Cardiol 34: 85-89. |
[101] |
Sacchetti A, Harris R, Patel K, et al. (1991) Emergency department presentation of renal dialysis patients: indications for EMS transport directly to dialysis centers. J Emerg Med 9: 141-144. doi: 10.1016/0736-4679(91)90320-F
![]() |
[102] |
McDonald SP, Tong B (2011) Morbidity burden of end-stage kidney disease in Australia: hospital separation rates among people receiving kidney replacement therapy. Nephrology (Carlton) 16: 758-766. doi: 10.1111/j.1440-1797.2011.01486.x
![]() |
[103] |
Herzog CA, Littrell K, Arko C, et al. (2007) Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116: 1465-1472. doi: 10.1161/CIRCULATIONAHA.107.696765
![]() |
[104] |
Sosnov J, Lessard D, Goldberg RJ, et al. (2006) Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 47: 378-384. doi: 10.1053/j.ajkd.2005.11.017
![]() |
[105] |
Jaffe AS, Apple FS (2012) The third Universal Definition of Myocardial Infarction--moving forward. Clin Chem 58: 1727-1728. doi: 10.1373/clinchem.2012.196832
![]() |
[106] |
Wu AH, Jaffe AS, Apple FS, et al. (2007) National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 53: 2086-2096. doi: 10.1373/clinchem.2007.095679
![]() |
[107] | Fahim MA, Hayen AD, Horvath AR, et al. (2015) Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clin Chem Lab Med 53: 715-722. |
[108] |
Michos ED, Wilson LM, Yeh HC, et al. (2014) Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med 161: 491-501. doi: 10.7326/M14-0743
![]() |
[109] | (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45: S1-153. |
[110] |
Yancy CW, Jessup M, Bozkurt B, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62: e147-239. doi: 10.1016/j.jacc.2013.05.019
![]() |
[111] |
Mueller T, Leitner I, Egger M, et al. (2015) Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta 445: 155-160. doi: 10.1016/j.cca.2015.03.033
![]() |
[112] |
Mueller T, Dieplinger B (2013) The Presage((R)) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 13: 13-30. doi: 10.1586/erm.12.128
![]() |
[113] | Lippi G, Cervellin G (2014) Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci 51: 13-29. |
[114] |
Weinberg EO, Shimpo M, De Keulenaer GW, et al. (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106: 2961-2966. doi: 10.1161/01.CIR.0000038705.69871.D9
![]() |
[115] |
Demyanets S, Speidl WS, Tentzeris I, et al. (2014) Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One 9: e95055. doi: 10.1371/journal.pone.0095055
![]() |
[116] |
Dieplinger B, Egger M, Haltmayer M, et al. (2014) Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem 60: 530-540. doi: 10.1373/clinchem.2013.209858
![]() |
[117] |
Bayes-Genis A, de Antonio M, Galan A, et al. (2012) Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14: 32-38. doi: 10.1093/eurjhf/hfr156
![]() |
[118] | Lippi G, Salvagno GL, Robuschi F, et al. (2014) Influence of dipyridamole stress echocardiography on galectin-3, amino-terminal B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T. Acta Cardiol 69: 377-383. |
[119] | Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9: 305-328. |
[120] |
Sharma UC, Pokharel S, van Brakel TJ, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-3128. doi: 10.1161/01.CIR.0000147181.65298.4D
![]() |
[121] | Suarez G, Meyerrose G (2014) Heart failure and galectin 3. Ann Transl Med 2: 86. |
[122] |
Chen A, Hou W, Zhang Y, et al. (2015) Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 182: 168-170. doi: 10.1016/j.ijcard.2014.12.137
![]() |
[123] |
Winter MP, Wiesbauer F, Alimohammadi A, et al. (2016) Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest 46: 386-391. doi: 10.1111/eci.12605
![]() |
[124] |
Yancy CW, Jessup M, Bozkurt B, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128: e240-327. doi: 10.1161/CIR.0b013e31829e8776
![]() |
[125] |
Hogas S, Schiller A, Voroneanu L, et al. (2016) Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. Angiology 67: 854-859. doi: 10.1177/0003319715623397
![]() |
[126] |
Gurel OM, Yilmaz H, Celik TH, et al. (2015) Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz 40: 788-794. doi: 10.1007/s00059-015-4303-6
![]() |
[127] |
de Boer RA, van der Velde AR, Mueller C, et al. (2014) Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther 28: 237-246. doi: 10.1007/s10557-014-6520-2
![]() |
[128] |
Hagstrom E, James SK, Bertilsson M, et al. (2016) Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 37: 1325-1333. doi: 10.1093/eurheartj/ehv491
![]() |
[129] |
Jougasaki M, Rodeheffer RJ, Redfield MM, et al. (1996) Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97: 2370-2376. doi: 10.1172/JCI118680
![]() |
[130] |
Nishikimi T, Saito Y, Kitamura K, et al. (1995) Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26: 1424-1431. doi: 10.1016/0735-1097(95)00338-X
![]() |
[131] |
Maisel A, Mueller C, Nowak R, et al. (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-2076. doi: 10.1016/j.jacc.2010.02.025
![]() |
[132] |
Giannopoulos G, Deftereos S, Panagopoulou V, et al. (2013) Copeptin as a biomarker in cardiac disease. Curr Top Med Chem 13: 231-240. doi: 10.2174/15680266113139990088
![]() |
[133] | Reid P, Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88: 1-17. |
[134] |
Nybo M, Rasmussen LM (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 159: 603-608. doi: 10.1530/EJE-08-0554
![]() |
[135] |
Rosenberg M, Zugck C, Nelles M, et al. (2008) Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 1: 43-49. doi: 10.1161/CIRCHEARTFAILURE.107.746172
![]() |
[136] |
Rabin KR, Kamari Y, Avni I, et al. (2005) Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 3: 465-471. doi: 10.1586/14779072.3.3.465
![]() |
[137] | Zoccali C, Mallamaci F, Panuccio V, et al. (2003) Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl: S98-102. |
[138] | Zoccali C, Mallamaci F, Tripepi G, et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141. |
[139] |
Yan AT, Yan RT, Spinale FG, et al. (2006) Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12: 514-519. doi: 10.1016/j.cardfail.2006.05.012
![]() |
[140] | Kecebas M, Gullulu S, Sag S, et al. (2014) Serum fetuin-A levels in patients with systolic heart failure. Acta Cardiol 69: 399-405. |
[141] |
Morrow DA, Cannon CP, Rifai N, et al. (2001) Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. Jama 286: 2405-2412. doi: 10.1001/jama.286.19.2405
![]() |
[142] |
Sandoval Y, Herzog CA, Love SA, et al. (2016) Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients. Clin Chem 62: 631-638. doi: 10.1373/clinchem.2015.251835
![]() |
1. | Hilla Behar, Naama Brenner, Yoram Louzoun, Coexistence of productive and non-productive populations by fluctuation-driven spatio-temporal patterns, 2014, 96, 00405809, 20, 10.1016/j.tpb.2014.06.002 | |
2. | Yoram Louzoun, Rebecca Mitchell, Hilla Behar, Ynte Schukken, Two state model for a constant disease hazard in paratuberculosis (and other bovine diseases), 2015, 46, 1297-9716, 10.1186/s13567-015-0189-9 | |
3. | N. Dori, H. Behar, H. Brot, Y. Louzoun, Family-size variability grows with collapse rate in a birth-death-catastrophe model, 2018, 98, 2470-0045, 10.1103/PhysRevE.98.012416 | |
4. | Hilla Behar, Yoram Louzoun, Commensal pathogens as a source of a coexistence mechanism, 2015, 370, 00225193, 45, 10.1016/j.jtbi.2015.01.030 | |
5. | H Behar, N Brenner, G Ariel, Y Louzoun, Fluctuations-induced coexistence in public goods dynamics, 2016, 13, 1478-3975, 056006, 10.1088/1478-3975/13/5/056006 | |
6. | A. B. Melka, N. Dori, Y. Louzoun, Survival induced by short-scale autocorrelations in birth-death-diffusion models with negative growth, 2023, 108, 2470-0045, 10.1103/PhysRevE.108.034103 |
Parameter | HiScreenTM SP FF | HiPrepTM SP FF |
Column length (mm) | 100 | 100 |
Column i.d. (mm) | 7.7 | 16 |
Median particle size (μm) | 90 | 90 |
Column voidage | 0.296 | 0.273 |
Particle voidage | 0.893 | 0.856 |
Total voidage | 0.917 | 0.895 |
Protein | LP and LF |
Concentration (mg/mL) | 0.2 |
Injection volume (μL) | 47*, 200** |
Flow velocity (cm/min) | 1.74, 2.50, 3.33, 4.50, 5.82, 6.67, 7.52*, 0.84, 1.00, 1.74, 2.00, 2.50, 2.88** |
Buffer | 20 mM NaH2SO4+ Na2HPO4, 1 M NaCl pH 6.7 |
Temperature (℃) | 22-22.5 |
*HiScreenTM column, **HiPrepTM column |
Protein | LP |
Concentration (mg/mL) | 0.02, 0.03, 0.06, 0.1, 0.5, 1 |
Flow velocity (cm/min) | 1.74, 2, 2.50, 2.80 |
Buffer | 20 mM NaH2SO4+ Na2HPO4, pH 6.7 |
Temperature (℃) | 22-22.5 |
Chromatography column | HiScreenTM SP FF | HiPrepTM SP FF | ||||||
Velocity (cm/min) | 3.333 | 4.946 | 5.828 | 7.527 | 0.836 | 2.488 | 2.985 | 3.333 |
Pe (-) | 35.01 ± 0.87 | 38.59 ± 0.91 | 37.49 ± 0.9 | 38.14 ± 0.97 | 190.3 ± 5.2 | 204.9 ± 4.6 | 196.7 ± 4.7 | 189 ± 5.4 |
Parameter | HiScreenTM SP FF | HiPrepTM SP FF |
Column length (mm) | 100 | 100 |
Column i.d. (mm) | 7.7 | 16 |
Median particle size (μm) | 90 | 90 |
Column voidage | 0.296 | 0.273 |
Particle voidage | 0.893 | 0.856 |
Total voidage | 0.917 | 0.895 |
Protein | LP and LF |
Concentration (mg/mL) | 0.2 |
Injection volume (μL) | 47*, 200** |
Flow velocity (cm/min) | 1.74, 2.50, 3.33, 4.50, 5.82, 6.67, 7.52*, 0.84, 1.00, 1.74, 2.00, 2.50, 2.88** |
Buffer | 20 mM NaH2SO4+ Na2HPO4, 1 M NaCl pH 6.7 |
Temperature (℃) | 22-22.5 |
*HiScreenTM column, **HiPrepTM column |
Protein | LP |
Concentration (mg/mL) | 0.02, 0.03, 0.06, 0.1, 0.5, 1 |
Flow velocity (cm/min) | 1.74, 2, 2.50, 2.80 |
Buffer | 20 mM NaH2SO4+ Na2HPO4, pH 6.7 |
Temperature (℃) | 22-22.5 |
Chromatography column | HiScreenTM SP FF | HiPrepTM SP FF | ||||||
Velocity (cm/min) | 3.333 | 4.946 | 5.828 | 7.527 | 0.836 | 2.488 | 2.985 | 3.333 |
Pe (-) | 35.01 ± 0.87 | 38.59 ± 0.91 | 37.49 ± 0.9 | 38.14 ± 0.97 | 190.3 ± 5.2 | 204.9 ± 4.6 | 196.7 ± 4.7 | 189 ± 5.4 |